Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1576-1582

  Ong, Chin Ann J ^a   Shapiro, Joel ^d   Nason, Katie S ^e   Davison, Jon M ^e   Liu, Xinxue ^a   Ross Innes, Caryn ^a   O'Donovan, Maria ^a   Dinjens, Winand N M ^d   Biermann, Katharina ^d   Shannon, Nicholas ^b   Worster, Susannah ^a   Schulz, Laura K E ^a   Luketich, James D ^e   Wijnhoven, Bas P L ^d   Hardwick, Richard H ^c   Fitzgerald, Rebecca C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b Cambridge Research Institute   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; SIRTUIN 2; TRIPARTITE MOTIF CONTAINING 44; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; EUROPE; FEMALE; GENOME ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CARRIER PROTEINS; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIRTUIN 2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876523738     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9636     Document Type: Article

References (33)

1. Pohl H, Sirovich B, Welch HG: Esophageal adenocarcinoma incidence: Are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19:1468- 1470, 2010
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
3. Edge SB, Byrd DR, Compton CC, et al (eds): AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010
4. Johansson J, DeMeester TR, Hagen JA, et al: En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg 139:627-631, 2004; discussion 631-633
5. Ong CA, Lao-Sirieix P, Fitzgerald RC: Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: Predictors of progression and prognosis. World J Gastroenterol 16:5669-5681, 2010
6. Lagarde SM, ten Kate FJ, Richel DJ, et al: Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 14:977-991, 2007 (Pubitemid 46175350)
7. Syrigos KN, Zalonis A, Kotteas E, et al: Targeted therapy for oesophageal cancer: An overview. Cancer Metastasis Rev 27:273-288, 2008
8. Villanacci V, Rossi E, Grisanti S, et al: Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: A translational approach. Minerva Gastroenterol Dietol 54: 347-353, 2008
9. Keld RR, Ang YS: Targeting key signalling pathways in oesophageal adenocarcinoma: A reality for personalised medicine? World J Gastroenterol 17:2781-2790, 2011
10. Goh XY, Rees JR, Paterson AL, et al: Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 60:1317-1326, 2011
11. Peters CJ, Rees JR, Hardwick RH, et al: A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139:1995.e15- 2004.e15, 2010
12. Reid BJ, Li X, Galipeau PC, et al: Barrett's oesophagus and oesophageal adenocarcinoma: Time for a new synthesis. Nat Rev Cancer 10:87- 101, 2010
13. Thallinger CMR, Raderer M, Hejna M: Esophageal cancer: A critical evaluation of systemic second-line therapy. J Clin Oncol 29:4709-4714, 2011
14. Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 12: 681-692, 2011
15. Leigh Y, Goldacre M, McCulloch P: Surgical specialty, surgical unit volume and mortality after oesophageal cancer surgery. Eur J Surg Oncol 35: 820-825, 2009
16. Mukherjee K, Chakravarthy AB, Goff LW, et al: Esophageal adenocarcinoma: Treatment modalities in the era of targeted therapy. Dig Dis Sci 55:3304-3314, 2010
17. Lagarde SM, Reitsma JB, Ten Kate FJ, et al: Predicting individual survival after potentially curative esophagectomy for adenocarcinoma of the esophagus or gastroesophageal junction. Ann Surg 248:1006-1013, 2008
18. Lagarde SM, Reitsma JB, de Castro SM, et al: Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br J Surg 94: 1361-1368, 2007 (Pubitemid 350144384)
19. Gaur P, Sepesi B, Hofstetter WL, et al: A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg 252:611-617, 2010
20. McManus DT, Olaru A, Meltzer SJ: Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 64:1561-1569, 2004 (Pubitemid 38428671)
21. Kim SM, Park YY, Park ES, et al: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS ONE 5:e15074, 2010
22. Martini M, Vecchione L, Siena S, et al: Targeted therapies: How personal should we go? Nat Rev Clin Oncol 9:87-97, 2012
23. Okines A, Cunningham D, Chau I: Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8:492-503, 2011
24. Dragovich T, Campen C: Anti-EGFR-targeted therapy for esophageal and gastric cancers: An evolving concept. J Oncol [epub ahead of print on July 14, 2009]
25. Kim HS, Vassilopoulos A, Wang RH, et al: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20:487-499, 2011
26. Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547-566, 2009
27. Katayama H, Sen S: Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta 1799:829-839, 2010
28. Diamond JR, Bastos BR, Hansen RJ, et al: Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 17:849-860, 2011
29. Hatakeyama S: TRIM proteins and cancer. Nat Rev Cancer 11:792-804, 2011
30. Urano T, Usui T, Takeda S, et al: TRIM44 interacts with and stabilizes terf, a TRIM ubiquitin E3 ligase. Biochem Biophys Res Commun 383:263- 268, 2009
31. Ong CAJ, Shannon NB, Lao-Sirieix P, et al: OC-017 TRIM44: From prognosis to therapy in oesophageal adenocarcinoma and breast cancer. Gut 61:A8, 2012 (suppl 2)
32. Perez EA, Reinholz MM, Hillman DW, et al: HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307-4315, 2010
33. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008 (Pubitemid 351264385)